AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Armata Pharmaceuticals, Inc. Director's Dealing 2009

May 19, 2009

34152_dirs_2009-05-19_d008a147-599b-4142-b4d9-e147333b8248.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TARGETED GENETICS CORP /WA/ (TGEN)
CIK: 0000921114
Period of Report: 2009-05-15

Reporting Person: Poston David J (Vice President and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2009-05-15	Common Stock	F	3085	$0.21	Disposed	68615	Direct
2009-05-17	Common Stock	F	3085	$0.21	Disposed	65530	Direct

Footnotes

F1: On May 15, 2009, 11,667 restricted shares of common stock vested for the reporting person and the reporting person surrendered 3,085 of such shares to the Company as payment for the withholding taxes due in connection with such vesting.

F2: On May 17, 2009, 11,667 restricted shares of common stock vested for the reporting person and the reporting person surrendered 3,085 of such shares to the Company as payment for the withholding taxes due in connection with such vesting.